CD276 and prostate carcinoma: While not functioning via the typical mechanism for immune checkpoint inhibition by focusing on blocking the inhibitory role of immune checkpoint molecules, these strategies may provide a novel alternative for exploiting the high levels of B7-H3 expression in prostate cancer.